Trials / Recruiting
RecruitingNCT07030712
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK-8294 Monotherapy in Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 67 (estimated)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
MK-8294, the study medicine, is a type of targeted therapy designed to treat certain solid tumors. The main goals of this study are to learn about the safety of MK-8294 and if people can tolerate it and find the highest dose level of MK-8294 that people can tolerate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-8294 | 30 µg via intravenous (IV) infusion |
| DRUG | MK-8294 | 100 µg via intravenous (IV) infusion |
| DRUG | MK-8294 | 300 µg via intravenous (IV) infusion |
| DRUG | MK-8294 | 1 mg via intravenous (IV) infusion |
| DRUG | MK-8294 | 3 mg via intravenous (IV) infusion |
| DRUG | MK-8294 | 10 mg via intravenous (IV) infusion |
| DRUG | MK-8294 | 30 mg via intravenous (IV) infusion |
| DRUG | MK-8294 | 70 mg via intravenous (IV) infusion |
| OTHER | CD8 PET Tracer | IV Infusion |
Timeline
- Start date
- 2025-07-23
- Primary completion
- 2027-08-23
- Completion
- 2027-08-23
- First posted
- 2025-06-22
- Last updated
- 2026-03-16
Locations
5 sites across 3 countries: United States, Israel, Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07030712. Inclusion in this directory is not an endorsement.